Biora Therapeutics Shared Detailed Results From Its Preclinical Study Of BioJet Systemic Oral Delivery Platform Delivering Glucagon-Like-Peptide-1 Receptor Agonist; Following Administration Of Semaglutide, Average Oral Bioavailability Was 37% (19%-60%)
Portfolio Pulse from Benzinga Newsdesk
Biora Therapeutics announced detailed results from its preclinical study of the BioJet Systemic Oral Delivery Platform, delivering Glucagon-Like-Peptide-1 Receptor Agonist. The average oral bioavailability of Semaglutide was 37% (19%-60%).
June 26, 2023 | 10:05 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biora Therapeutics' preclinical study results for the BioJet Systemic Oral Delivery Platform show promising oral bioavailability of Semaglutide, potentially boosting the company's stock.
The positive preclinical study results for Biora Therapeutics' BioJet Systemic Oral Delivery Platform indicate a promising future for the product. The average oral bioavailability of Semaglutide was 37%, which is a significant achievement in the biotech industry. This news could potentially attract investors and boost the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100